CoChat
Sign Up
Cited by 288Dementia and Cognitive Impairment ResearchCancer-related cognitive impairment studiesNeurological Disease Mechanisms and Treatments

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Risk Factors for the Progression of Mild Cognitive Impairment to Dementia

Open access
Campbell, Noll L., Unverzagt, Fred, LaMantia, Michael A., Khan, Babar A., Boustani, Malaz A.·2013·Clinics in Geriatric Medicine
DOI 10.1016/j.cger.2013.07.009PMC PMC5915285
Open this paper in CoChat — free account

Abstract

The increasing prevalence of cognitive impairment among the older adult population warrants attention to the identification of practices that may minimize the progression of early forms of cognitive impairment, including the transitional stage of mild cognitive impairment (MCI), to permanent stages of dementia. This article identifies both markers of disease progress and risk factors linked to the progression of MCI to dementia. Potentially modifiable risk factors may offer researchers a point of intervention to modify the effect of the risk factor and to minimize the future burden of dementia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cger.2013.07.009

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The study adjusted for confounders associated with both exposure and outcome, identified based on literature review and clinical knowledge.

    “We adjusted for confounders associated with both the exposure and the outcome, which were identified based on the literature review and clinical knowledge [19–21].”

    From Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study (2023) · cites this paper as [19]

    The Summary identifies the paper as a review of risk factors for progression from MCI to dementia, so it could inform the citing authors’ literature-based choice of variables. The Comorbidity and Other Clinical Characteristics section describes adjustments made in another study, but does not say that this review adjusted for confounders or that the citing authors selected variables associated with both their exposure and outcome using clinical knowledge. In the citing sentence, “We adjusted” describes the citing authors’ own method, not this source’s. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 96

  1. Ganguli, 2008, Mild cognitive impairment: challenging issues, Am J Geriatr Psychiatry, 16, 339, 10.1097/JGP.0b013e31816c3fdb · DOI
  2. Winblad, 2004, Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment, J Intern Med, 256, 240, 10.1111/j.1365-2796.2004.01380.x · DOI · Paper page
  3. Petersen, 2004, Mild cognitive impairment as a diagnostic entity, J Intern Med, 256, 183, 10.1111/j.1365-2796.2004.01388.x · DOI · Paper page
  4. Petersen, 1995, Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals, JAMA, 273, 1274, 10.1001/jama.1995.03520400044042 · DOI
  5. Graham, 1997, Prevalence and severity of cognitive impairment with and without dementia in an elderly population, Lancet, 349, 1793, 10.1016/S0140-6736(97)01007-6 · DOI
  6. Ebly, 1995, Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging, Arch Neurol, 52, 612, 10.1001/archneur.1995.00540300086018 · DOI
  7. Kral, 1962, Senescent forgetfulness: benign and malignant, Can Med Assoc J, 86, 257
  8. Levy, 1994, Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization, Int Psychogeriatr, 6, 63, 10.1017/S1041610294001626 · DOI
  9. Plassman, 2008, Prevalence of cognitive impairment without dementia in the United States, Ann Intern Med, 148, 427, 10.7326/0003-4819-148-6-200803180-00005 · DOI
  10. Yaffe, 2006, Subtype of mild cognitive impairment and progression to dementia and death, Dement Geriatr Cogn Disord, 22, 312, 10.1159/000095427 · DOI
  11. Mitchell, 2008, Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis, J Neurol Neurosurg Psychiatry, 79, 1386, 10.1136/jnnp.2007.142679 · DOI
  12. Raffaitin, 2009, Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study, Diabetes Care, 32, 169, 10.2337/dc08-0272 · DOI
  13. Solfrizzi, 2010, Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing, J Neurol Neurosurg Psychiatry, 81, 433, 10.1136/jnnp.2009.181743 · DOI
  14. Vanhanen, 2006, Association of metabolic syndrome with Alzheimer disease: a population-based study, Neurology, 67, 843, 10.1212/01.wnl.0000234037.91185.99 · DOI
  15. Razay, 2007, The metabolic syndrome and Alzheimer disease, Arch Neurol, 64, 93, 10.1001/archneur.64.1.93 · DOI
  16. Bowler, 2005, Vascular cognitive impairment, J Neurol Neurosurg Psychiatry, 76, v35, 10.1136/jnnp.2005.082313 · DOI
  17. Petersen, 2005, Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med, 352, 2379, 10.1056/NEJMoa050151 · DOI · Paper page
  18. Doody, 2009, Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial, Neurology, 72, 1555, 10.1212/01.wnl.0000344650.95823.03 · DOI
  19. Unverzagt, 2012, ACTIVE cognitive training and rates of incident dementia, J Int Neuropsychol Soc, 18, 669, 10.1017/S1355617711001470 · DOI · Paper page
  20. Aisen, 2008, Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial, Curr Alzheimer Res, 5, 73, 10.2174/156720508783884602 · DOI
  21. Snitz, 2009, Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial, JAMA, 302, 2663, 10.1001/jama.2009.1913 · DOI
  22. DeKosky, 2008, Ginkgo biloba for prevention of dementia: a randomized controlled trial, JAMA, 300, 2253, 10.1001/jama.2008.683 · DOI
  23. Jack, 2005, Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI, Neurology, 65, 1227, 10.1212/01.wnl.0000180958.22678.91 · DOI · Paper page
  24. Whitwell, 2008, MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment, Neurology, 70, 512, 10.1212/01.wnl.0000280575.77437.a2 · DOI · Paper page
  25. McEvoy, 2009, Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment, Radiology, 251, 195, 10.1148/radiol.2511080924 · DOI · Paper page
  26. Bakkour, 2009, The cortical signature of prodromal AD: regional thinning predicts mild AD dementia, Neurology, 72, 1048, 10.1212/01.wnl.0000340981.97664.2f · DOI
  27. Murphy, 2010, Six-month atrophy in MTL structures is associated with subsequent memory decline in elderly controls, Neuroimage, 53, 1310, 10.1016/j.neuroimage.2010.07.016 · DOI
  28. Becker, 2011, Amyloid-beta associated cortical thinning in clinically normal elderly, Ann Neurol, 69, 1032, 10.1002/ana.22333 · DOI · Paper page
  29. Fjell, 2009, One-year brain atrophy evident in healthy aging, J Neurosci, 29, 15223, 10.1523/JNEUROSCI.3252-09.2009 · DOI · Paper page
  30. McDonald, 2009, Regional rates of neocortical atrophy from normal aging to early Alzheimer disease, Neurology, 73, 457, 10.1212/WNL.0b013e3181b16431 · DOI · Paper page
  31. Saykin, 2006, Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI, Neurology, 67, 834, 10.1212/01.wnl.0000234032.77541.a2 · DOI
  32. de Leon, 2007, Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease, Ann N Y Acad Sci, 1097, 114, 10.1196/annals.1379.012 · DOI
  33. Tondelli, 2012, Structural MRI changes detectable up to ten years before clinical Alzheimer's disease, Neurobiol Aging, 33, 825.e25, 10.1016/j.neurobiolaging.2011.05.018 · DOI
  34. Geroldi, 2006, Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment, J Neurol Neurosurg Psychiatry, 77, 1219, 10.1136/jnnp.2005.082651 · DOI
  35. Breteler, 1994, Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study, Neurology, 44, 1246, 10.1212/WNL.44.7.1246 · DOI
  36. Scarpelli, 1994, MRI and pathological examination of post-mortem brains: the problem of white matter high signal areas, Neuroradiology, 36, 393, 10.1007/BF00612126 · DOI
  37. Longstreth, 1996, Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study, Stroke, 27, 1274, 10.1161/01.STR.27.8.1274 · DOI · Paper page
  38. van der Flier, 2005, Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study, J Neurol Neurosurg Psychiatry, 76, 1497, 10.1136/jnnp.2005.064998 · DOI
  39. Yoshita, 2006, Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD, Neurology, 67, 2192, 10.1212/01.wnl.0000249119.95747.1f · DOI · Paper page
  40. de Groot, 2001, Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study, Neurology, 56, 1539, 10.1212/WNL.56.11.1539 · DOI
  41. Devine, 2013, Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia?, Int Psychogeriatr, 25, 120, 10.1017/S1041610212000932 · DOI
  42. Debette, 2010, The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis, BMJ, 341, c3666, 10.1136/bmj.c3666 · DOI · Paper page
  43. Brickman, 2012, Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community, Arch Neurol, 69, 1621, 10.1001/archneurol.2012.1527 · DOI
  44. Bombois, 2008, Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients, Stroke, 39, 2046, 10.1161/STROKEAHA.107.505206 · DOI
  45. Hansson, 2006, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, 5, 228, 10.1016/S1474-4422(06)70355-6 · DOI · Paper page
  46. Mattsson, 2012, Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment, J Alzheimers Dis, 30, 767, 10.3233/JAD-2012-120019 · DOI
  47. Fagan, 2006, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann Neurol, 59, 512, 10.1002/ana.20730 · DOI · Paper page
  48. Heister, 2011, Predicting MCI outcome with clinically available MRI and CSF biomarkers, Neurology, 77, 1619, 10.1212/WNL.0b013e3182343314 · DOI
  49. Vos, 2012, Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI, Neurobiol Aging, 33, 2272, 10.1016/j.neurobiolaging.2011.12.017 · DOI
  50. van Rossum, 2012, Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease, J Alzheimers Dis, 29, 319, 10.3233/JAD-2011-111694 · DOI
  51. Lee, 2009, Peripheral cytokines and chemokines in Alzheimer's disease, Dement Geriatr Cogn Disord, 28, 281, 10.1159/000245156 · DOI
  52. Kamer, 2009, TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects, J Neuroimmunol, 216, 92, 10.1016/j.jneuroim.2009.08.013 · DOI
  53. Seppala, 2010, Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study, J Neurol Neurosurg Psychiatry, 81, 1123, 10.1136/jnnp.2010.205757 · DOI
  54. Le Bastard, 2010, Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients, J Alzheimers Dis, 21, 291, 10.3233/JAD-2010-091501 · DOI
  55. Lui, 2010, Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging, J Alzheimers Dis, 20, 1233, 10.3233/JAD-2010-090249 · DOI
  56. Lewczuk, 2010, Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing, Exp Neurol, 223, 366, 10.1016/j.expneurol.2009.07.024 · DOI
  57. Blennow, 2009, Use of CSF biomarkers in Alzheimer's disease clinical trials, J Nutr Health Aging, 13, 358, 10.1007/s12603-009-0043-8 · DOI
  58. Kester, 2010, Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment, Neurobiol Aging, 31, 539, 10.1016/j.neurobiolaging.2008.07.024 · DOI
  59. Schupf, 2008, Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease, Proc Natl Acad Sci U S A, 105, 14052, 10.1073/pnas.0805902105 · DOI · Paper page
  60. Guntert, 2010, Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease, J Alzheimers Dis, 21, 585, 10.3233/JAD-2010-100279 · DOI
  61. Gupta, 2011, Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging, Neurology, 76, 1091, 10.1212/WNL.0b013e318211c352 · DOI · Paper page
  62. Llano, 2013, Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease, Alzheimer Dis Assoc Disord, 27, 233, 10.1097/WAD.0b013e31826d597a · DOI
  63. Choo, 2013, Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients, J Alzheimers Dis, 33, 929, 10.3233/JAD-2012-121489 · DOI
  64. Tschanz, 2006, Conversion to dementia from mild cognitive disorder: the Cache County Study, Neurology, 67, 229, 10.1212/01.wnl.0000224748.48011.84 · DOI
  65. Elias-Sonnenschein, 2011, Predictive value of APOE-epsilon4 allele for progression from MCI to AD-type dementia: a meta-analysis, J Neurol Neurosurg Psychiatry, 82, 1149, 10.1136/jnnp.2010.231555 · DOI · Paper page
  66. Tyas, 2007, Transitions to mild cognitive impairments, dementia, and death: Findings from the nun study, Am J Epidemiol, 165, 1231, 10.1093/aje/kwm085 · DOI · Paper page
  67. Rodriguez-Rodriguez, 2013, Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease, J Neural Transm, 120, 807, 10.1007/s00702-012-0920-x · DOI
  68. Guo, 2013, The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome, Eur Arch Psychiatry Clin Neurosci, 263, 325, 10.1007/s00406-012-0349-0 · DOI
  69. Zhou, 2012, Risk classification in mild cognitive impairment patients for developing Alzheimer's disease, J Alzheimers Dis, 30, 367, 10.3233/JAD-2012-112117 · DOI
  70. Campbell, 2010, Use of anticholinergics and the risk of cognitive impairment in an African American population, Neurology, 75, 152, 10.1212/WNL.0b013e3181e7f2ab · DOI · Paper page
  71. Schubert, 2006, Comorbidity profile of dementia patients in primary care: are they sicker?, J Am Geriatr Soc, 54, 104, 10.1111/j.1532-5415.2005.00543.x · DOI
  72. Murray, 2007, Pharmacist intervention to improve medication adherence in heart failure: a randomized trial, Ann Intern Med, 146, 714, 10.7326/0003-4819-146-10-200705150-00005 · DOI
  73. Nahin, 2009, Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people, J Am Geriatr Soc, 57, 1197, 10.1111/j.1532-5415.2009.02329.x · DOI
  74. Murray, 2002, Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans, Arch Intern Med, 162, 2090, 10.1001/archinte.162.18.2090 · DOI
  75. Launer, 2000, Midlife blood pressure and dementia: the Honolulu-Asia aging study, Neurobiol Aging, 21, 49, 10.1016/S0197-4580(00)00096-8 · DOI · Paper page
  76. Kivipelto, 2001, Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study, BMJ, 322, 1447, 10.1136/bmj.322.7300.1447 · DOI · Paper page
  77. Hanon, 2008, Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function and Systolic Blood Pressure Reduction open-label study, J Hypertens, 26, 1642, 10.1097/HJH.0b013e328301a280 · DOI
  78. Lyketsos, 2005, Population-based study of medical comorbidity in early dementia and “cognitive impairment, no dementia (CIND)”: association with functional and cognitive impairment: The Cache County Study, Am J Geriatr Psychiatry, 13, 656
  79. Solfrizzi, 2011, Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging, Neurobiol Aging, 32, 1932, 10.1016/j.neurobiolaging.2009.12.012 · DOI
  80. Li, 2012, Clinical predictors of cognitive decline in patients with mild cognitive impairment: the Chongqing aging study, J Neurol, 259, 1303
  81. Clerici, 2012, Does vascular burden contribute to the progression of mild cognitive impairment to dementia?, Dement Geriatr Cogn Disord, 34, 235, 10.1159/000343776 · DOI
  82. Ravaglia, 2006, Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors, Dement Geriatr Cogn Disord, 21, 51, 10.1159/000089515 · DOI
  83. DeCarli, 2004, Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia, Neurology, 63, 220, 10.1212/01.WNL.0000130531.90205.EF · DOI
  84. Wolf, 2000, Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study, Int J Geriatr Psychiatry, 15, 803, 10.1002/1099-1166(200009)15:9<803::AID-GPS190>3.0.CO;2-W · DOI
  85. Xu, 2004, Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study, Neurology, 63, 1181, 10.1212/01.WNL.0000140291.86406.D1 · DOI
  86. Xu, 2010, Accelerated progression from mild cognitive impairment to dementia in people with diabetes, Diabetes, 59, 2928, 10.2337/db10-0539 · DOI · Paper page
  87. Li, 2011, Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease, Neurology, 76, 1485, 10.1212/WNL.0b013e318217e7a4 · DOI · Paper page
  88. Hoffman, 2009, Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons, Neurology, 72, 1720, 10.1212/01.wnl.0000345881.82856.d5 · DOI
  89. Bettermann, 2012, Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study, J Stroke Cerebrovasc Dis, 21, 436, 10.1016/j.jstrokecerebrovasdis.2010.11.002 · DOI
  90. Peters, 2012, Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study, Am J Geriatr Psychiatry, 20, 416, 10.1097/JGP.0b013e318211057d · DOI
  91. Lyketsos, 2006, Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease, Am J Geriatr Psychiatry, 14, 561, 10.1097/01.JGP.0000221334.65330.55 · DOI
  92. Peters, 2013, Neuropsychiatric symptoms as risk factors for progression from CIND to Dementia: The Cache County Study, Am J Geriatr Psychiatry, 10.1016/j.jagp.2013.01.049 · DOI · Paper page
  93. Richard, 2012, Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects, Dement Geriatr Cogn Disord, 33, 204, 10.1159/000338239 · DOI
  94. Modrego, 2004, Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study, Arch Neurol, 61, 1290, 10.1001/archneur.61.8.1290 · DOI
  95. Palmer, 2007, Predictors of progression from mild cognitive impairment to Alzheimer disease, Neurology, 68, 1596, 10.1212/01.wnl.0000260968.92345.3f · DOI
  96. Richard, 2013, Late-life depression, mild cognitive impairment, and dementia, JAMA Neurol, 70, 374, 10.1001/jamaneurol.2013.603 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Campbell, N. L., Unverzagt, F., LaMantia, M. A., Khan, B. A., & Boustani, M. A.
Affiliations
  • Regenstrief Institute (US)
  • Indiana University School of Medicine (US)
Corresponding author
Campbell, Noll L.
ORCID
Venue
Clinics in Geriatric Medicine
Publisher
Elsevier BV
Published
2013-11
Volume
29
Issue
4
Pages
873-893
ISSN
0749-0690 (ISSN-L)
DOI
10.1016/j.cger.2013.07.009
PMC
PMC5915285
OpenAlex
W2012603004
Cited by
288
References
14
Citations by year
2026: 35 · 2025: 48 · 2024: 46 · 2023: 49 · 2022: 40 · 2021: 17 · 2020: 16 · 2019: 12 · 2018: 6 · 2017: 3 · 2016: 9 · 2015: 1 · 2014: 6
FWCI
0.60
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Clinics in Geriatric Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • PMC
Funders
  • Agency for Healthcare Research and Quality (R01HS019818-01, R01HS019818)
  • National Institute on Aging (K23AG043476)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
mild cognitive impairment, dementia progression, risk factors, disease progression biomarkers, modifiable risk factors, dementia prevention, older adults, cognitive impairment
MeSH terms
Aged, Dementia, Humans, Risk Factors, Disease Progression, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review